83 related articles for article (PubMed ID: 10745488)
21. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Syvänne M
Duodecim; 1999; 115(10):1167-73. PubMed ID: 11877856
[No Abstract] [Full Text] [Related]
23. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
de Teresa Galván E; Jiménez Navarro M
Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
[No Abstract] [Full Text] [Related]
24. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
25. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
Kanbay M; Yildirir A; Bozbas H; Ulus T; Bilgi M; Muderrisoglu H; Akcay A; Ozdemir FN
Ren Fail; 2005; 27(3):297-303. PubMed ID: 15957546
[TBL] [Abstract][Full Text] [Related]
26. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
Brotons Cuixart C; Maiques Galán A
Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
[No Abstract] [Full Text] [Related]
27. Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Le Moyec L; Valensi P; Charniot JC; Hantz E; Albertini JP
NMR Biomed; 2005 Nov; 18(7):421-9. PubMed ID: 16075416
[TBL] [Abstract][Full Text] [Related]
28. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Bennett MT; Johns KW; Bondy GP
Lipids Health Dis; 2007 Jun; 6():15. PubMed ID: 17565701
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
30. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
Delahaye F; De Gevigney G
Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
[TBL] [Abstract][Full Text] [Related]
31. ALLHAT: a saga of missed opportunities.
McInnes GT
J Hum Hypertens; 2003 Jun; 17(6):373-7. PubMed ID: 12764398
[No Abstract] [Full Text] [Related]
32. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
[TBL] [Abstract][Full Text] [Related]
33. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
Magen E; Viskoper R; Mishal J; Priluk R; Berezovsky A; Laszt A; London D; Yosefy C
Isr Med Assoc J; 2004 Dec; 6(12):742-6. PubMed ID: 15609886
[TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering medications: what the new guidelines and data mean to women.
Schwartz JB
J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
[No Abstract] [Full Text] [Related]
35. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
36. Familial dysbetalipoproteinemia: a potentially fatal disorder.
Bari AU; Hashim R; Rahman SB; Hussain M
J Coll Physicians Surg Pak; 2008 Aug; 18(8):506-8. PubMed ID: 18798589
[TBL] [Abstract][Full Text] [Related]
37. Basic approach to managing hyperglycemia for the nonendocrinologist.
Deeg MA
Am J Cardiol; 2005 Aug; 96(4A):37E-40E. PubMed ID: 16098842
[TBL] [Abstract][Full Text] [Related]
38. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
Piechowski-Jóźwiak B; Bogousslavsky J
Acta Neurol Belg; 2005 Jun; 105(2):57-61. PubMed ID: 16076057
[TBL] [Abstract][Full Text] [Related]
40. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Kitta Y; Kobayashi T; Mende A; Kugiyama K
Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
